Affordable flow cytometry for enumeration of absolute CD4(+ )T-lymphocytes to identify subtype C HIV-1 infected adults requiring antiretroviral therapy (ART) and monitoring response to ART in a resource-limited setting by Zijenah, Lynn S et al.
BioMed  Central
Page 1 of 6
(page number not for citation purposes)
Journal of Translational Medicine
Open Access Research
Affordable flow cytometry for enumeration of absolute CD4+ 
T-lymphocytes to identify subtype C HIV-1 infected adults requiring 
antiretroviral therapy (ART) and monitoring response to ART in a 
resource-limited setting
Lynn S Zijenah*1, Gerard Kadzirange2, Simon Madzime3, Margaret Borok4, 
Chiedza Mudiwa1, Ocean Tobaiwa1, Mary Mucheche5, 
Simbarashe Rusakaniko6 and David A Katzenstein7
Address: 1Department of Immunology, College of Health Sciences University of Zimbabwe, Harare, Zimbabwe, 2Chitungwiza Central Hospital, 
Chitungwiza, Zimbabwe, 3Department of Obstetrics and Gynaecology, College of Health Sciences University of Zimbabwe, Harare, Zimbabwe, 
4Department of Medicine, College of Health Sciences University of Zimbabwe, Harare, Zimbabwe, 5Zimbabwe AIDS Prevention Project, Harare, 
Zimbabwe, 6Department of Community Medicine, College of Health Sciences University of Zimbabwe, Harare, Zimbabwe and 7Division of 
Infectious Diseases and AIDS Research, Stanford University Medical School, Stanford, California, USA
Email: Lynn S Zijenah* - LZIJENAH@HEALTHNET.ZW; Gerard Kadzirange - gkadzirange@zappuz.co.zw; 
Simon Madzime - smadzime@healthnet.zw; Margaret Borok - mborok@medsch.uz.ac.zw; Chiedza Mudiwa - cmudiwa@yahoo.com; 
Ocean Tobaiwa - otobaiwa@yahoo.com; Mary Mucheche - mucheche@yahoo.com; Simbarashe Rusakaniko - srusakaniko@medsch.uz.ac.zw; 
David A Katzenstein - davidkk@stanford.edu
* Corresponding author    
Abstract
Background: The World Health Organization (WHO)'s "3 × 5 program" has spurred efforts to place 3 million people
on combination antiretroviral therapy (ART) for treatment of AIDS in resource-limited countries. Paradoxically, the cost
of CD4+ T-lymphocyte count essential for decision-making to commence HIV positive adults on ART as well as for
monitoring responses to ART remains unaffordable in most resource-limited countries. Thus, low-cost methods for
enumerating CD4+ T-lymphocyte are urgently needed.
Objective: To evaluate Cyflow cytometry (Cyflow SL, Partec, Munster, Germany) for enumeration of absolute CD4+
T-lymphocyte in subtype C HIV-1 seropositive subjects using FACSCount (Becton and Dickinson, Immunocytometry
Systems, San Jose, CA, USA) as the "predicate method".
Methods: A total of 150 HIV-1 seropositive subjects were included in the evaluation exercise. Fifty-eight specimens
were collected from pregnant HIV-1 seropositive women (subtype C drug resistance study). Twenty-seven specimens
were collected from women and their spouses with AIDS followed in a Duke ART study to assess the immunologic and
virologic responses to generic ART, comprising Stavudine, Lamivudine and Nevirapine (Stalanev, Varichem Labs, Harare,
Zimbabwe). Sixty-five specimens were collected from AIDS patients enrolled in an ongoing Kaposi Sarcoma (KS) study
to investigate impact of ART on KS progression. Enumeration of CD4+ T-lymphocytes using FACSCount is routinely
conducted for all the three studies. The Medical Research Council of Zimbabwe and Medicines Control Authority of
Zimbabwe approved the studies. Whole blood was collected in EDTA vacutainer tubes and aliquoted into two tubes
(200  μL in each). CD4+ T-lymphocyte counts were enumerated using a Cyflow counter, in the Department of
Immunology and a FACSCount in the Department of Obstetrics and Gynaecology within 6 hours of phlebotomy
following manufacturers' instructions.
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Results: Using linear regression analysis, there was a very strong correlation (R = 0.991) between the overall CD4+ T-
lymphocyte counts obtained by FACSCount and those obtained by Cyflow. When data analysis was stratified by study
groups, there was a strong correlation between the FACSCount and Cyflow CD4+ T-lymphocyte counts from subjects
in the three independent studies; Subtype C resistance (R2 = 0.987), Duke ART (R2 = 0.980) and KS (R2 = 0.994), Table 1.
Using Bland-Altman plots, the overall, absolute CD4+ T lymphocytes obtained by the two methods were in excellent
agreement (mean difference 1.21, 95% Confidence Interval {CI): -2.1 to 3.3). For the 0–250 CD4+ T-lymphocytes range,
the CD4 counts obtained using FACSCount were also in good agreement with those obtained using Cyflow counter
(mean difference = 2.6 cells/μL, 95% CI: -1.1 to 6.3). Similarly, in the 251–500 (mean difference 1.0, cells/μL, 95% CI: -
3.7 to 5.6) and the 501–1200 (mean difference = 0.29 cells/μL, 95% CI: -8.1 to 8.7) CD4 T-lymphocytes range, good
agreement was observed.
Conclusion: The Cyflow counter is as accurate as the FACSCount in enumerating absolute CD4+ T-lymphocytes in the
range 1–1200 cells/μL. Cyflow cytometry is relatively affordable, easy to use technology that is useful not only in
identifying HIV seropositive individuals who require ART but also for monitoring immunologic responses to ART.
Background
The World Health Organization (WHO) "3 × 5 program"
has spurred efforts to place 3 million people on combina-
tion antiretroviral therapy (ART) for treatment of AIDS in
resource-limited countries [1,2]. This has been made pos-
sible by reduction in price of proprietary ARVs and the
introduction of generic versions of these drugs. Paradoxi-
cally, the cost of CD4+ T-lymphocyte count essential for
decision-making to commence ART for HIV positive
adults and to monitor responses to ART remains unafford-
able in most resource-limited countries. Although, some
resource-limited countries that cannot access affordable
CD4+ T-lymphocyte enumeration may use clinical criteria
in accordance with WHO recommendations for com-
mencing HIV seropositive individuals on ART [3], CD4+ T-
lymphocyte count remains an important measure of
immune response, and provide laboratory criteria for
stopping co-trimoxazole prophylaxis.
Laboratory-based WHO recommendations for decisions
to commence adult HIV-infected individuals on ART are
largely based on absolute CD4+  T-lymphocyte counts.
Flow cytometry is the gold standard for accurate and auto-
mated measurements of absolute T-lymphocyte subset
profiles. Flow cytometric techniques are not only expen-
sive, but require sophisticated equipment and reagents as
well as highly trained personnel. Furthermore, in
resource-limited countries ready access to technical sup-
port and quality assurance programs for flow cytometry
are often not readily available. Non-flow cytometric meth-
ods for counting absolute CD4+ T-lymphocytes such as
the manual magnetic bead Dynabead technique have also
been evaluated [4,5] but are also considered expensive,
labor intensive and can only accommodate low sample
throughput [6].
Current clinical flow cytometric methods use either dual
or single platforms for enumeration of absolute T-lym-
phocyte subpopulations. Dual platforms rely on a combi-
nation of flow cytometric percentages and white blood
cells (WBC) obtained from haematological analyzers to
obtain absolute numbers of T-lymphocytes. On the other
hand, single platform cytometers are dedicated flow
cytometers with direct absolute counting facility. Previous
studies have shown that dual platforms have a higher
inter-laboratory percent coefficient of variation (%CV) of
absolute CD4+ T-lymphocytes compared to single plat-
forms [7]. The higher %CV was attributed to use of differ-
ent haematological analyzers, with no external quality
assurance and internal quality control for WBC used in
dual platforms [8]and references therein.] Single plat-
form flow cytometers may allow the efficient and accurate
enumeration of T-lymphocyte subpopulations in clinical
settings where large numbersof patients are receiving care
[9].
Recently, great strides have been made in developing easy
to use affordable single platform flow cytometric methods
for enumerating absolute CD4+ T-lymphocytes. For exam-
ple, Janossy and colleagues introduced primary CD4 gat-
ing on volumetric flow cytometry for absolute CD4+ T-
lymphocyte counts without microbeads or haematology
[10]. However, this method was developed using the 'state
of the art' flow cytometers (Cytoron Ortho and FACSCal-
ibur) with the attendant capacity and costs requirements.
Recently, an increasing number of point of care less
expensive methods to measure absolute CD4+  T-lym-
phocyte counts have been developed. These include the
development and evaluation of simplified single platform
flow cytometric methods using a low cost flow cytometer
that can be powered from a car battery or by solar panels
(Cyflow SL, Partec, Munster, Germany) by Cassens and
colleagues [11,12], modification of a commercially avail-
able 4-parameter flow cytometer, Luminex 100 (Luminex,
Austin Texas, USA) to a compact portable prototypeJournal of Translational Medicine 2006, 4:33 http://www.translational-medicine.com/content/4/1/33
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instrument that can operate with a 12-volt rechargeable
battery [13] and Guava PCA System (Guava Technologies,
Hayward, CA, USA).
The objective of the current study was to evaluate single
platform Cyflow cytometry (Cyflow SL, Partec, Munster,
Germany) for enumeration of absolute CD4+  T-lym-
phocytes among subtype C HIV-1 seropositive subjects
using single platform FACSCount (Becton and Dickinson,
Immunocytometry Systems, San Jose, CA, USA) as the
predicate method.
Methods
A total of 150 HIV-1 seropositive subjects were included
in the evaluation exercise. Fifty-eight specimens were col-
lected from pregnant HIV-1 seropositive women (subtype
C drug resistance study). Twenty-seven specimens were
collected from women and their spouses with AIDS fol-
lowed in a study to assess the immunologic and virologic
responses to generic ART (Stalanev, Varichem Labs,
Harare, Zimbabwe) comprising Stavudine, Lamivudine
and Nevirapine. Sixty-five specimens were collected from
AIDS patients enrolled in an ongoing Kaposi Sarcoma
(KS) study to investigate impact of ART on KS progression.
Enumeration of CD4+ T-lymphocytes using FACSCount is
routinely conducted for all the three studies. In the current
evaluation of the Cyflow Counter, the FACS counter is
thus used as the "predicate method". The Medical
Research Council of Zimbabwe and Medicines Control
Authority of Zimbabwe approved the studies.
Whole blood was collected in EDTA vacutainer tubes
(Becton-Dickinson, Mt View, California) and aliquoted
into two tubes (200 μL in each). One tube was sent to the
Department of Immunology and the second to the
Department of Obstetrics and Gynaecology for enumera-
tion of CD4+ T-lymphocytes using a Cyflow counter and a
FACSCount respectively within 6 hours of phlebotomy
following manufacturers' instructions. The two independ-
ent medical laboratory scientists in the two Departments
who conducted the enumeration of the CD4+  T-lym-
phocytes were blinded to each other's results.
Cyflow reagents and consumables were used according to
the manufacturer's instructions. Briefly, 20 μL of whole
EDTA blood was pipetted into a Partec test tube. Ten
microlitres of CD4-phycoeryrthrin conjugated mono-
clonal antibody supplied by Partec was added to the tube
containing whole blood and the reactants incubated for
15 minutes at room temperature. Following incubation,
800 μL of no lyse buffer, supplied by Partec were added to
the tube and gently vortex-mixed. The tube was then
plugged into the Cyflow counter for automatic counting.
The histogram and absolute counts are displayed and
printed automatically. The histogram shows direct count-
ing result in terms of absolute CD4+ T-lymphocytes/μL.
The CD4+ T-lymphocytes with high fluorescence appear in
a prominent peak at the right of the histogram, whereas
the weaker but also CD4+ monocytes appear to the left
without any overlap with CD4+ T-lymphocytes.
For FACSCount analysis, 50 μL of whole EDTA blood was
added to the CD4 FACSCount reagent tube containing
anti-CD3 and anti-CD4 monoclonal antibodies, sample
diluent, and reference beads. The samples were then incu-
bated at room temperature for 60 minutes and subse-
quently run on the FACSCount.
Statistical analysis
Correlation coefficient and linear regression analysis were
used to compare results obtained by FACSCount and
Cyflow. CD4+ T-lymphocytes counts obtained by FACS-
Count were plotted on the X-axis against counts obtained
by Cyflow counter on the Y-axis. Bland-Altman plots [14]
were used to test the agreement between the two methods
by plotting the mean of the values obtained by the two
methods on the X-axis and the difference between the two
methods on the Y-axis. The mean difference between the
two methods (bias) and its 95% confidence intervals, and
the limits of agreement, defined as bias ± 2 standard devi-
ation were calculated. Sub-analysis of data was also per-
formed separately for the three independent studies from
which subjects were recruited. Data analysis was also strat-
ified according to the range (0–250; 251–500 and 501–
1200 cells/μL) of absolute CD4+ T-lymphocyte counts to
determine any range-dependent differences between the
two methods.
Results
A total of 150 specimens from HIV seropositive patients
with CD4+ T-lymphocyte counts ranging from 1 to 1200
cells/μL were evaluated. The overall median CD4+ T-lym-
phocyte count of the cohort using the FACSCount was
371 cells/μL (Interquartile range {IQR: 240–513), whilst
that from the Cyflow counter was 362 cells/μL {IQR:
244–530).
Linear regression plot of absolute CD4+ T-lymphocytes
obtained by Cyflow and FACSCount is shown in Figure 1.
Correlation analysis of absolute CD4+  T-lymphocytes
obtained by the two methods is shown in Table 1. There
was a very strong correlation (R = 0.995, R2 = 0.991)
between the overall CD4+ T-lymphocyte counts obtained
by FACSCount and that obtained by Cyflow counter
(Table 1).
When data analysis was stratified by study groups, there
was a strong correlation between the FACSCount and
Cyflow counter CD4+ T-lymphocyte counts from subjects
in the three independent studies; Subtype C resistance (RJournal of Translational Medicine 2006, 4:33 http://www.translational-medicine.com/content/4/1/33
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= 0.993, R2 = 0.987), Duke ART (R = 0.990, R2 = 0.980)
and KS (R = 0.997, R2 = 0.994), Table 1. Similarly strong
correlations were observed when data analysis was strati-
fied by CD4+ T-lymphocytes range; 0–250 (R = 0.983, R2
= 0.966), 251–500 (R = 0.948, R2 = 0.898) and 501–1200
(R = 0.984, R2 = 0.968) cells/μL.
Figure 2 shows the Bland-Altman plot comparing CD4+ T-
lymphocytes obtained by Cyflow and FACSCount. The
overall, absolute CD4+ T lymphocytes obtained by the two
methods were in excellent agreement (mean difference =
1.21, 95% Confidence Interval (CI: -2.1 to 4.5). For the 0–
250 CD4+ T-lymphocytes range, the CD4 counts obtained
using FACSCount were also in good agreement with those
obtained using Cyflow counter (mean difference = 2.6
cells/μL, 95% CI: -1.1 to 6.3), Table 2. Similarly, in the
251–500 (mean difference = 0.96, cells/μL, 95% CI:-3.7 to
5.6) and the 501–1200 (mean difference = -0.29, cells/μL,
95% CI: -8.1 to 8.7) CD4+ T-lymphocytes ranges, good
agreement was observed (Table 2).
WHO recommends that HIV seropositive adults with
CD4+ T-lymphocyte ≤ 200 cells/μL should be commenced
on ART [3], we thus evaluated the accuracy of the Cyflow
counter in identifying these individuals. The Cyflow coun-
ter concordantly identified all but one subject (26/27)
with CD4+ T-lymphocyte counts of ≤200 cells/μL as deter-
mined by FACSCount. The CD4+ T-lymphocyte counts for
the subject with discordant results were 210 and 199 cells/
μL from FACSCount and Cyflow respectively.
Discussion
ARVs have become increasingly available in resource-lim-
ited countries in the past few years, mainly because of
drastic reductions in prices of proprietary and generic
drugs. However, the cost of enumerating absolute CD4+ T-
lymphocyte required for decision-making to commence
HIV infected individuals on ART and monitoring
responses to ART remains unaffordable for most resource-
limited countries. Recently, development of affordable
practical technologies for enumeration of absolute CD4+
T-lymphocyte may play a critical role in making ART avail-
able to all those that need it in developing countries.
In the current study, we have shown that the single plat-
form Partec Cyflow counter can accurately identify HIV
seropositive subjects with less than 200 CD4 cells, who
are eligible for ART, and conversely, those with > 200 CD4
cells who may not require continued Co-trimoxazole
prophylaxis. Furthermore, we have also shown that Partec
Cyflow counter can provide accurate CD4+ T-lymphocyte
counts for patients who are on ART.
Our results are in agreement with those reported from a
recent multicenter evaluation involving eight hospitals in
Europe, Africa and Asia [12] as well as independent eval-
uations in several other resource-limited countries that
have evaluated Partec Cyflow counter for enumeration of
absolute CD4+ T-lymphocyte counts albeit using various
Table 1: Correlation analysis of CD4+T-lymphocyte counts obtained by FACSCount and Cyflow
Study group Mean difference CD4 SD R2 y Intercept 95% CI
All (N = 150) 1.21 20.40 0.991 0.998x + 1.807 1.807 -5.09 to 8.70
Subtype C drug resistance (N = 58) 2.40 18.11 0.987 1.0009x + 1.951 1.951 -15.46 to 19.36
Duke ART (N = 27) -2.04 18.88 0.980 0.9628x + 15.708 15.708 -6.51 to 37.92
Kaposi Sarcoma ART (N = 65) -0.18 15.77 0.994 0.9949x + 1.432 1.432 -5.83 to 8.70
Range of CD4+ T-lymphocytes Mean difference CD4 SD R2 y Intercept 95% CI
0–250 CD4+ cells/μL (N = 40) 2.60 11.94 0.967 0.9653x + 3.022 3.0216 -7.25 to 13.30
251–500 CD4+ cells/μL (N = 69) 0.96 19.59 0.898 0.9275x + 25.443 25.443 -2.64 to 53.53
501–1200 CD4+ cells/μL (N = 41) 0.29 27.49 0.968 0.9456x + 37.090 37.090 -2.04 to 76.24
Correlation and R2 values for CD4+ T-lymphocytes obtained  by Cyflow and FACSCount Figure 1
Correlation and R2 values for CD4+ T-lymphocytes obtained 
by Cyflow and FACSCount.
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versions of Cyflow counter. In Senegal, where subtypes A
and D HIV-1 predominate, an excellent correlation was
observed when Partec Cyflow SL blue (equipped with 3
fluorescence and 2 light scatter detectors) was compared
to FACScan and FACSCount [15]. In another West African
country, Nigeria, with similar co-epidemics, the Cyflow
technique was reported to be more precise and cost-effec-
tive than the Dynabead method [6]. A study in Malawi,
where subtype C predominates, field evaluation of Cyflow
reported a correlation coefficient of 0.92 (95% CI 0.89–
0.95) when compared to FACSCount with trained tech-
nologists finding Cyflow counter procedures simple to
run and the instrument easy to manipulate [16]. A good
correlation between CD4+ T-lymphocyte counts obtained
by Cyflow and FACSCount has also been reported in Thai-
land where subtypes B HIV-1 predominates and CRF
Table 2: Bland-Altman analysis comparison of Cyflow versus FACSCount absolute CD4+ T-lymphocyte counts
Range of CD4+ T-lym-
phocyte counts
N Positive and negative 
LOA (cells/μL)
Mean difference (bias) 95% CI of the mean
0–1200 CD4+ cells/μL (All) 150 42 to -40 1.21 -2.1 to 3.3
0–250 CD4+ cells/μL 40 27 to -21 2.6 -1.1 to 6.3
251–500 CD4+ cells/μL 69 40 to -38 0.96 -3.7 to 5.6
501–1200 CD4+ cells/μL 41 55 to -55 0.29 -8.1 to 8.7
N; Number tested; CI, confidence interval; LOA, limits of agreement
Bland-Altman plot comparing absolute CD4+ T-lymphocyte counts obtained by Cyflow and FACSCount Figure 2
Bland-Altman plot comparing absolute CD4+ T-lymphocyte counts obtained by Cyflow and FACSCount. The blue line indicates 
the bias (mean difference) and the dotted lines are limits of agreement (mean ± 2 SD). Mean = 1.21 (95% CI: -2.1 to 3.3); limits 
of agreement between +42 and -40.
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AE_01 [17]. Most importantly, when comparing two
methods of clinical measurements, in all these studies,
Bland-Altman plots showed good agreement between
Cyflow and the "predicate method".
There is an urgent need to develop, evaluate and imple-
ment more affordable and easy to use technology for enu-
merating CD4+  T-lymphocyte counts to commence
patients on ART as well as for monitoring immunologic
responses to ART to make ART available to all those who
need it, particularly in resource-limited countries.
Currently in Zimbabwe, the cost of CD4+ T-lymphocyte
count is US$56. This cost is revised upward quarterly.
According to the manufacturer of Cyflow, a CD4+ T-lym-
phocyte count using their machine and reagents should
cost only US$2.50 (2 Euros). Although the purchasing
price of FACSCount and Cyflow counter are comparable
(US$30 000-50 000), the FACSCount reagents are more
expensive than those for the Cyflow. The Cyflow counter
also has a high throughput and as many as 200 specimens
can be run per day, making it ideal for use in Zimbabwe,
a country with one of the highest prevalence of HIV glo-
bally.
In conclusion, the Cyflow counter is as accurate as the
FACSCount in enumerating absolute CD4+  T-lym-
phocytes in the range 1–1200 cells/μL. Cyflow cytometry
is relatively affordable, easy to use technology that is use-
ful not only in identifying HIV seropositive individuals
who require ART but also for monitoring immunologic
responses to ART.
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